EGFR and metastatic colorectal cancer: derived implications from previous clinical trials and cohort studies that KRAS mutations may have a stronger effect on prognosis in patients with metastatic colorectal cancer, and discussed possible biomarkers to recognize resistance to EGFR inhibition (32).